カテゴリ： GlobalData, アメリカ, 企業調査

GeoVax Labs Inc (GOVX)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：GeoVax Labs Inc (GOVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012269
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：63
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
GeoVax Labs Inc (GeoVax) is a clinical-stage biotechnology company, which develops human vaccines for diseases caused by HIV, cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus on human immunodeficiency virus (HIV), Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. The company developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

GeoVax Labs Inc (GOVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 12
GeoVax Labs Enters into Partnership with American Gene Technologies 13
GeoVax Labs Research Agreement with Georgia State University Research Foundation 14
GeoVax Labs Enters into Research Agreement with Burnet Institute 15
GeoVax Labs Enters into Co-Development Agreement with ViaMune 16
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 17
GeoVax Labs Enters into R&D Agreement with USAMRIID 18
GeoVax Labs Enters into Research Agreement with University of Georgia 19
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 20
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 21
Licensing Agreements 22
GeoVax Labs Enters into Licensing Agreement with Valneva 22
Equity Offering 23
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 23
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 24
GeoVax Labs Raises USD6 Million in Private Placement 25
GeoVax Labs Completes Private Placement Of Shares For US$1.6 Million 26
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For US$2.2 Million 27
GeoVax Completes Second Tranche Of Private Placement Of Units For US$0.25 Million 28
GeoVax Labs Inc – Key Competitors 29
GeoVax Labs Inc – Key Employees 30
GeoVax Labs Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 32
Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 35
May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 37
Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 38
Nov 11, 2016: GeoVax Reports 2016 Third Quarter Financial Results and Provides Corporate Update 39
Aug 05, 2016: GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update 41
May 04, 2016: GeoVax Reports 2016 First Quarter Financial Results 43
Mar 16, 2016: GeoVax Reports 2015 Year-End Financial Results And Provides Corporate Update 44
Corporate Communications 45
Dec 14, 2016: GeoVax Announces Appointment of Farshad Guirakhoo, PhD as Chief Scientific Officer 45
Product News 46
12/05/2016: GeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses 46
08/02/2016: GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials 47
07/27/2016: GeoVax Reports Progress with Hemorrhagic Fever Vaccine Program 48
06/21/2016: GeoVax Discusses Zika Vaccine Development at American Society for Virology’s 35th Annual Meeting 49
06/13/2016: GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting 50
05/18/2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 51
05/02/2016: GeoVax Presents at Zika Virus Scientific Conference 52
04/18/2016: GeoVax Provides Update on Zika Vaccine Program 53
04/14/2016: GeoVax Awarded $1.4M NIH Grant 54
04/03/2017: GeoVax Awarded $658,000 NIH Grant for its HIV Vaccine Program 55
03/07/2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 56
Feb 03, 2016: GeoVax to Develop Vaccine Against Zika Virus 57
Product Approvals 58
Jun 30, 2016: GeoVax Announces Filing of Investigational New Drug Application for HIV Human Clinical Trial 58
Clinical Trials 59
Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 59
Oct 20, 2016: GeoVax HIV Vaccine Clinical Data Presented at HIVR4P Conference 60
Other Significant Developments 61
Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
GeoVax Labs Inc, Deals By Therapy Area, 2011 to YTD 2017 9
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 12
GeoVax Labs Enters into Partnership with American Gene Technologies 13
GeoVax Labs Research Agreement with Georgia State University Research Foundation 14
GeoVax Labs Enters into Research Agreement with Burnet Institute 15
GeoVax Labs Enters into Co-Development Agreement with ViaMune 16
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 17
GeoVax Labs Enters into R&D Agreement with USAMRIID 18
GeoVax Labs Enters into Research Agreement with University of Georgia 19
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 20
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 21
GeoVax Labs Enters into Licensing Agreement with Valneva 22
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 23
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 24
GeoVax Labs Raises USD6 Million in Private Placement 25
GeoVax Labs Completes Private Placement Of Shares For US$1.6 Million 26
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For US$2.2 Million 27
GeoVax Completes Second Tranche Of Private Placement Of Units For US$0.25 Million 28
GeoVax Labs Inc, Key Competitors 29
GeoVax Labs Inc, Key Employees 30
GeoVax Labs Inc, Subsidiaries 31

★海外企業調査レポート[GeoVax Labs Inc (GOVX)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Engepack Embalagens SA：企業の戦略・SWOT・財務情報
    Engepack Embalagens SA - Strategy, SWOT and Corporate Finance Report Summary Engepack Embalagens SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • WEC Energy Group Inc (WEC)-エネルギー分野：企業M&A・提携分析
    Summary WEC Energy Group, Inc. (WEC) is a diversified holding company that carries out the generation and distribution of electricity in southeastern Wisconsin, east central Wisconsin, northern Wisconsin, and Michigan's Upper Peninsula; and transports and distributes natural gas in the upper peninsu …
  • Enlight Renewable Energy Ltd (ENLT)：企業の財務・戦略的SWOT分析
    Summary Enlight Renewable Energy Ltd (Enlight Renewable), a subsidiary of Eurocom Group, is a renewable energy company that invests, develops, finances, constructs, operates and manages electricity production projects from renewable energy sources. The company develops photovoltaic technology by whi …
  • Petra Energy Berhad (PENERGY)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petra Energy Berhad (Petra Energy) is an integrated brown field service provider for the upstream oil and gas industry. The company offers services such as designing, procurement, engineering, installation, fabrication, commissioning, maintenance, construction and project management. It also …
  • SCHOTT AG：企業の戦略・SWOT・財務情報
    SCHOTT AG - Strategy, SWOT and Corporate Finance Report Summary SCHOTT AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Bukwang Pharm Co Ltd (003000)：製薬・医療：M&Aディール及び事業提携情報
    Summary Bukwang Pharm Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexid, thioctacid, levovir, legalon, Orfil, azeptin, lonasen, ixel, and asima, among others. Its pipeline products comprise …
  • Sun Resources NL (SUR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Sun Resources NL (Sun Resources) is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources. Its projects include Delta Oil Project, …
  • Jumbo SA：企業の戦略・SWOT・財務分析
    Jumbo SA - Strategy, SWOT and Corporate Finance Report Summary Jumbo SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Bitauto Holdings Limited：企業のM&A・事業提携・投資動向
    Bitauto Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bitauto Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • U.S. Concrete Inc (USCR)：企業の財務・戦略的SWOT分析
    Summary U.S. Concrete Inc (US Concrete) is a construction company that manufactures and markets ready-mixed concrete and aggregates. The company’s aggregate products include crushed stone, sand and gravel used in commercial, industrial and public works. It also provides specialty products such as ra …
  • SPX Corp (SPXC)：電力：M&Aディール及び事業提携情報
    Summary SPX Corp (SPX) is a specialized engineered solutions provider. It offers highly engineered products, technologies, and solutions. The company’s portfolio includes heating, ventilation, and air conditioning (HVAC) products, detection and measurement equipment, and engineered solutions. It off …
  • Xtant Medical Holdings Inc (XTNT)：医療機器：M&Aディール及び事業提携情報
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings Inc, is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteowr …
  • Indiana Resources Limited：企業の戦略・SWOT・財務分析
    Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Indiana Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Ngai Hing Hong Co Ltd (1047)
    Ngai Hing Hong Co Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Svenska Petroleum Exploration AB：石油・ガス：M&Aディール及び事業提携情報
    Summary Svenska Petroleum Exploration AB (Svenska Petroleum), a subsidiary of Petroswede AB is an oil and gas company that offers offshore oil exploration and production. The company operates 3D Sendji data and acquisition of new 3D data in Kaba area to explore for the pre-salt. It has oil and gas p …
  • China Yangtze Power Co Ltd (600900)：電力：M&Aディール及び事業提携情報
    Summary China Yangtze Power Co Ltd (CYPC), a subsidiary of China Three Gorges Corp is a renewable energy company that offers power distribution and sale services. The company offers services such as services of power distribution covering various areas including consultancy, energy procurement, dist …
  • Brain Resource Ltd (BRC)：企業の財務・戦略的SWOT分析
    Summary Brain Resource Ltd (BRL) is a healthcare service provider that offers therapies. The company carries out research and development of brain products. Its products comprise iSPOT, Total Brain and MyBrainSolutions. BRL’s MyBrainSolutions is a brain health solution to know and train brain for pe …
  • PTC India Ltd (PTC)：電力：M&Aディール及び事業提携情報
    Summary PTC India Ltd (PTC) formerly Power Trading Corporation of India Limited, is a provider of power trading solutions. The company is a public-private partnership entity initiated by the government of India. It carries out trading activities which include, long term trading of power generated fr …
  • Spherix Inc (SPEX)：企業の財務・戦略的SWOT分析
    Spherix Inc (SPEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Hokuriku Electric Power Co (9505)：企業の財務・戦略的SWOT分析
    Hokuriku Electric Power Co (9505) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆